Article Text

Download PDFPDF
Systematic review
No evidence for switching antidepressants in treatment-resistant depressed patients

Statistics from


  • Competing interests MT has received consultancy fees, speakers fees and/or grants from: Adolar, AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly, Forest Pharmaceuticals, GlaxoSmithKline, Janssen Pharmaceutica, Lundbeck, MedAvante, Merck, Neuronetics, Novartis, Pharmaneuroboost, Otsuka, Pfizer, PGx Pharmaceuticals, Sepracror, Shire US, Supernus Pharmaceuticals, Takeda and Transcept.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.